Business
InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier
InMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nInMed Pharmaceuticals Announces Appointment of Veteran Biotech CFO, Jeff Charpentier\nCanada NewsWire\nVANCOUVER, Dec. 15, 2016\n\n\n\nVANCOUVER, Dec. 15, 2016 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or \"the Company\") (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Jeff Charpentier, CPA, CA as InMed's Chief Financial Officer & Corporate Secretary.   \n\nMr. Charpentier is a veteran of the biopharmaceutical industry with over 25 years of experience. Jeff has held a series of senior financial roles at several public and private companies in the pharmaceutical and technology sectors where he led multiple equity financings, raising in excess of $150M and concluded a number of corporate partnering/product sale transactions. Jeff previously served as CFO for Lifebank Corp. (through to successful company sale in 2012), Inex Pharmaceuticals Corporation (now Arbutus Biopharma Corp.), and Chromos Molecular Systems Inc. Jeff has a Bachelor of Commerce degree from the University of British Columbia and is a member of the Chartered Professional Accountants of BC.\n\n\"We are extremely pleased to welcome Jeff to the InMed executive team,\" notes Eric A. Adams, President & CEO. \"This is an exciting stage in InMed's development and Jeff's extensive track-record in helping health care organizations plan and execute growth strategies makes him an ideal fit for our organization.  As we enter 2017, the complexity and diversity of our drug development plans will increase and having a seasoned biotech financial executive onboard is vital.\"\n\nOn behalf of the Board of InMed, the Company would like to extend its warmest gratitude to the outgoing CFO, Terese Gieselman for her numerous valuable contributions to InMed since its inception and w...